Page 12 - Structure Prediction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DeepMind has recently solved a 50-year-old protein-related challenge that has notched up the level of biology for scientists.

One of science's great puzzles is being solved by artificial intelligence and the answers shared freely on the internet. How can life sciences companies make the most of DeepMind's discoveries while protecting their own?

Burst of Protein Structure Predictions from DeepMind, EMBL July 23, 2021 The tremors that shook the life sciences community last December were mere prelude. Back then, at a biennial protein-prediction competition, an artificial intelligence (AI) tool called AlphaFold delivered an outstanding performance, predicting structures quite as well as X-ray crystallography or cryo-electron microscopy (cryo-EM), the gold standard experimental techniques. Now, AlphaFold has produced an eruption: a release of more than 350,000 protein structure predictions. Besides covering nearly the entire human proteo...

Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery. A prime example of the future potential of AI is in revolutionizing the way we diagnose, monitor, and treat multiple sclerosis (MS), thereby advancing our understanding of the disease course. Today, MS continues to be...

PharmCADD, a Busan, South Korea-based Artificial Intelligence (AI) and Physics-based drug discovery company, raised USD 16m in Series B funding. The round, which brought total funding raised to date to USD 22m, was led by strategic investors Huons, Samyang Holdings and SD BIOSENSOR and financial investors KTB Network, Daily Partners, DSC Investment, KDB Capital, Maple Investment and KB Securities. The company intends to use the funds to launch the U.S. and India-based branches, to advance its AI & Physics-based drug discovery platform technology, Pharmulator™, to expand R&D manpower, and c...